NervGen Pharma 公司——净收益将用于推进Nvg-291临床研究及一般公司用途

美股速递
May 22

NervGen Pharma 公司宣布,此次融资所得净收益将主要用于推进其核心候选药物Nvg-291的临床研究,并支持公司的一般运营与战略发展。此举旨在加速该疗法的开发进程,为未来的商业化奠定基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10